The U.S. Centers for Medicare & Medicaid Services starting Jan. 1, 2024, will require all 340B covered entities—hospital and grantee—to use claims modifiers to identify drugs as having been purchased through 340B when they bill for separately payable Medicare Part
…
Drug manufacturer Viatris will give 340B covered entities credits on requests for purchases of dozens of NDCs at higher than 340B ceiling price during the first 11 days of August, the company says in a notice on the U.S. Health
…
Private practice oncologists have paid for a study to model what would happened in 2023 if Medicare paid 340B hospitals for physician administered drugs based on a survey of those hospitals’ drug acquisition costs taken during the COVID pandemic’s darkest
…
Drug manufacturer Merck is providing refunds for charges above 340B ceiling prices on 23 NDCs purchased during Q4 2019, Q3 2021, and Q2 2022.
The U.S. Health Resources and Services Administration posted Merck’s Nov. 21 notice about the repayments on
…
The U.S. Health Resources and Services Administration has slightly adjusted the dates of the first of four periods in 2023 during which eligible entities may register themselves, their child sites, and their contract pharmacies to participate in the 340B program.
…
Drug manufacturer Novo Nordisk for the third time this year has announced refunds for 340B overcharges due to revisions of Medicaid pricing data.
The U.S. Health Resources and Services Administration posted the company’s notice to covered entities on its website
…
Ryan White Clinics for 340B Access told a federal district judge last week it needs time to assess how proposed new 340B administrative dispute resolution regulations, if finalized, could affect the 340B overcharging claims it brought against AstraZeneca under the
…
As we were the first to report on Tuesday morning, the Biden administration has proposed major changes to the 340B program administrative dispute resolution process, including stripping the Centers for Medicare & Medicaid Services and the Department of Health and
…
Groups that represent 340B covered entities said they looked forward to studying the federal government’s proposal Tuesday to revamp the 340B administrative dispute process. But they expressed concern that drug manufacturers still are not being punished for denying 340B pricing
…
A Richmond, Va., citizen’s group is continuing the fight against a health system accused of 340B program misuse at a hospital in a low-income, majority Black neighborhood in the wake of the death of U.S. Rep. A. Donald McEachin (D-Va.),
…
×
*Sign up for news summaries and alerts from 340B Report